Johnson & Johnson has “entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure.” J&J's website has the news.
Heart failure “is a global health burden associated with impaired quality of life, frequent hospitalizations, increasing health-care costs, and high rates of premature death. V-Wave’s cardiovascular implant technology specifically targets heart failure with reduced ejection fraction (HFrEF). In HFrEF, a patient’s heart muscle has insufficient ability to pump blood containing oxygen and nutrients to the body.”
V-Wave’s Ventura Interatrial Shunt (IAS) “is a novel implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure by creating a shunt between the left and right atrium, thereby reducing cardiovascular events and heart failure hospitalizations.” The device is “placed in the heart through a minimally invasive catheter-based procedure and has the potential to fill a significant treatment gap between guideline directed medical therapies (GDMT) as a first line therapy and highly invasive cardiac replacement therapies.” It also addresses an “unmet need for approximately 800,000 patients who experience HFrEF in the U.S. every year.”
